Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

The First Affiliated Hospital with Nanjing Medical University is the lead sponsor of 205 current clinical trials in our China register. 132 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Sintilimab, Adebrelimab and Orelabrutinib. The most-studied condition is Breast Cancer.

ClinicalTrials.gov trials by status

Recruiting13264%
Not yet open5225%
Active, closed126%
By invitation94%

Trials by phase

Phase 26833%
Not applicable5024%
Observational4522%
Phase 3126%
Phase 494%
Phase 184%
Phase EARLY_PHASE184%
Phase 1/252%

Clinical trials sponsored by The First Affiliated Hospital with Nanjing Medical University

205 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL NCT07195799 · Non-Hodgkin Lymphoma Drug: Linperlisib	Phase 2	Recruiting	2024-12	China
RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies NCT07105735 · ClinicalTrials.gov ↗ · Autoimmune Diseases Refractory to Standard Therapies Drug: Allogeneic CAR-T	Phase 1	Recruiting	2025-08	China
Effect of PCI on Clinical Prognosis of Chronic Coronary Artery Occlusion NCT06542653 · ClinicalTrials.gov ↗ · Coronary Atheroscleroses	Observational	Recruiting	2023-09	China
Pyrotinib in Women With High-risk in Early Stage Breast Cancer NCT05834764 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer Drug: Pyrotinib	Phase 2	Recruiting	2023-04	China
Brachial Versus Femoral Access for Carotid Artery Stenting NCT06557135 · ClinicalTrials.gov ↗ · Carotid Artery Stenosis Without Infarction (Disorder), Ischemic Stroke	Not applicable	Recruiting	2024-09	China
Robotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy NCT06895447 · ClinicalTrials.gov ↗ · Gastric Cancers	Phase 2	Recruiting	2024-11	China
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study NCT07065435 · ClinicalTrials.gov ↗ · HER2 + Breast Cancer Drugs: Bevacizumab, Disitamab Vedotin, Pyrotinib	Phase 2	Recruiting	2024-01	China
Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A Single-arm Phase II Trial NCT07731828 · ClinicalTrials.gov ↗ · Cervical Neoplasms Drug: Adebrelimab	Phase 2	Recruiting	2026-08	China
Impact of Pet Cats on Nasal and Gut Microbiota in Patients With Cat Allergen Allergy NCT07110311 · ClinicalTrials.gov ↗ · Allergic Rhinitis	Observational	Recruiting	2024-11	China
Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age NCT06354218 · ClinicalTrials.gov ↗ · Esophageal Carcinoma Drug: Serplulimab	Phase 2	Recruiting	2023-12	China
A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance Imaging for the Detection of Intracardiac Thrombus NCT06146751 · ClinicalTrials.gov ↗ · Heart Aneurysm Drug: Ferumoxytol	Observational	Recruiting	2023-11	China
The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection NCT06287541 · ClinicalTrials.gov ↗ · Non Muscle Invasive Bladder Cancer	Not applicable	Recruiting	2023-07	China
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study NCT06254690 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Docetaxel, Trastuzumab	Phase 2	Recruiting	2024-01	China
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma NCT07418190 · ClinicalTrials.gov ↗ · Relapsed/Refractory Follicular Lymphoma	Phase 2	Recruiting	2026-02	China
A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer. NCT07622836 · ClinicalTrials.gov ↗ · TNBC, Adjuvant Therapy, Lymph Node Positive	Not applicable	Recruiting	2026-06	China
Immunotherapy for Hepatocellular Carcinoma NCT06241326 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Immunotherapy	Observational	Recruiting	2024-03	China
A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients NCT07671378 · ClinicalTrials.gov ↗ · CLL (Chronic Lymphocytic Leukemia)	Phase 2	Recruiting	2026-06	China
Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel) NCT06656624 · ClinicalTrials.gov ↗ · Advanced Breast Cancer	Phase 2	Recruiting	2024-08	China
A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer NCT07263386 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma Drug: Sintilimab	Phase 2	Recruiting	2025-10	China
Gestational Lifestyle & Outcomes Wellness NCT07263412 · ClinicalTrials.gov ↗ · GDM	Observational	Recruiting	2025-02	China
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML NCT06232694 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Not applicable	Recruiting	2024-01	China
Lactobacillus Vaginalis Capsules for Treatment of Vulvovaginal Atrophy in Young Breast Cancer Patients NCT05974449 · ClinicalTrials.gov ↗ · Breast Cancer Female	Phase 2	Recruiting	2023-08	China
Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study NCT07446452 · ClinicalTrials.gov ↗ · HER2-low Breast Cancer Drugs: Bevacizumab, Disitamab Vedotin	Phase 2	Recruiting	2024-01	China
Safety and Efficacy of SC101 Via Perirenal Fat Injection for Resistant Hypertension in Patients With Moderate to Severe Chronic Kidney Disease NCT07483372 · ClinicalTrials.gov ↗ · Resistant Arterial Hypertension, Chronic Kidney Disease (Stage 3-4)	Phase 1	Recruiting	2026-03	China
Hypofractionated Radiation Fractionation in Breast Cancer Patients With Implant-Based Reconstruction NCT06830083 · ClinicalTrials.gov ↗ · Breast Cancer	Not applicable	Recruiting	2025-01	China
Robot-assisted Laparoscopic Partial Nephrectomy Via the Extraperitoneal Approach in the Prone Position Versus the Lateral Position NCT06572501 · ClinicalTrials.gov ↗ · Renal Tumor, Prone Position, Robotic Assisted Partial Nephrectomy	Not applicable	Recruiting	2023-08	China
A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL NCT05931263 · ClinicalTrials.gov ↗ · Newly Diagnosed Peripheral T-cell Lymphoma	Phase 3	Recruiting	2023-06	China
A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer NCT06555471 · ClinicalTrials.gov ↗ · Gastric Cancer Drugs: Capecitabine, Sintilimab, Tegafur Gimeracil Oteracil	Phase 2	Recruiting	2024-08	China
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma NCT06838910 · ClinicalTrials.gov ↗ · Thymic Carcinoma, Thymoma Drug: Anlotinib	Phase 2	Recruiting	2025-03	China
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL NCT05950997 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia Drugs: Acalabrutinib, Obinutuzumab	Not applicable	Recruiting	2024-04	China
Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases NCT07558850 · ClinicalTrials.gov ↗ · Rheumatoid Arthritis, Dermatomyositis, Systemic Lupus Erythematosus	Not applicable	Recruiting	2026-05	China
A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer NCT07438106 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Cancer With KRAS G12D Mutation Drug: HRS-4642	Phase 2	Recruiting	2026-01	China
Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE NCT06607276 · ClinicalTrials.gov ↗ · Cholangiocarcinoma Cancer, Adebrelimab (SHR-1316)	Phase 2	Recruiting	2024-09	China
The Risk Factors Related to Rupture Flow-related Aneurysms in Posterior AVM NCT07050381 · ClinicalTrials.gov ↗ · Arteriovenous Malformation of Central Nervous System, Aneurysm, Ruptured, Aneurysmatic Subarachnoid Haemorrhage	Observational	Recruiting	2025-06	China
Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease NCT05461820 · ClinicalTrials.gov ↗ · Graves Disease, Relapse, Treatment Drug: Methimazole	Phase 4	Recruiting	2018-05	China
Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM NCT06341595 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastric Cancer Metastatic to Regional Lymph Nodes Drugs: Oxaliplatin, Sintilimab, Tegafur Gimeracil Oteracil	Phase 2	Recruiting	2024-04	China
Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC NCT05775419 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Chemotherapy Effect, Side Effect of Drug	Not applicable	Recruiting	2021-06	China
Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis NCT07263425 · ClinicalTrials.gov ↗ · Leptomeningeal Metastasis of HER2-positive Breast Cancer Drug: Administration of Thiotepa	Phase 2	Recruiting	2025-10	China
Safety of Robotic Surgery for GISTs at Special Anatomic Sites NCT07405125 · ClinicalTrials.gov ↗ · Gastrointenstinal Stromal Tumor (GIST)	Not applicable	Recruiting	2026-02	China
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma NCT07277439 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	2025-12	China
The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD) NCT06335836 · ClinicalTrials.gov ↗ · Social Isolation, SCD, Subjective Cognitive Decline	Observational	Recruiting	2024-03	China
High Resolution Diffusion Weighted Imaging in Prostate NCT06636747 · ClinicalTrials.gov ↗ · Prostate Cancer, Prostate Disease	Observational	Recruiting	2023-08	China
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma NCT06696742 · ClinicalTrials.gov ↗ · Bladder (Urothelial, Transitional Cell) Cancer Drugs: Cisplatin, Clostridium butyricum, Gemcitabine	Phase 2	Recruiting	2024-02	China
Ultrasound-Enhanced Delivery of Compound TXA Solution in Melasma NCT07202156 · ClinicalTrials.gov ↗ · Melasma (Facial Melasma)	Not applicable	Recruiting	2024-10	China
Omission of ALND in Breast Cancer Patients With Axillary pCR NCT05939830 · ClinicalTrials.gov ↗ · Axillary Lymph Node Dissection, Pathological Complete Response, Neoadjuvant Systemic Therapy	Not applicable	Recruiting	2023-09	China
Study on the Thrombolytic Effect of Platelet Membrane Coated Tenecteplase on Human Arterial Thrombus NCT07712445 · ClinicalTrials.gov ↗ · Arterial Thrombosis	Observational	Recruiting	2026-06	China
A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer NCT06735287 · ClinicalTrials.gov ↗ · Bladder Cancer, NMIBC	Not applicable	Recruiting	2024-12	China
A Multicenter Prospective Randomized Controlled Clinical Trial Comparing Constant (5%) Versus Sequential (5%-2%) Oxygen Concentration Embryo Culture Protocols in Assisted Reproductive Technology NCT07050537 · ClinicalTrials.gov ↗ · Fertility Issues, Blastocyst IVF, Embryo Culture	Not applicable	Recruiting	2025-03	China
Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk NCT06685289 · ClinicalTrials.gov ↗ · Biliary Malignant Tumors Drugs: Capecitabine, Donafenib	Phase 2	Recruiting	2024-11	China
Omission of SLNB in CN0 Early Breast Cancer NCT05935150 · ClinicalTrials.gov ↗ · Breast Cancer, Clinically Assessed Negative Axillary Lymph Nodes, Sentinel Lymph Node	Not applicable	Recruiting	2023-06	China
Catheter Ablation in Atrial Fibrillation Patients With HFpEF (STABLE-SR IV Trial) NCT06125925 · ClinicalTrials.gov ↗ · Atrial Fibrillation, HFpEF - Heart Failure With Preserved Ejection Fraction	Not applicable	Recruiting	2023-11	China
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study NCT06770296 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 1	Recruiting	2024-11	China
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy NCT06958705 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Drugs: Acalabrutinib, Ibrutinib, Orelabrutinib	Phase 2	Recruiting	2025-12	China
The Ameliorative Effects of GLP-1RA on Diabetic Cardiac Autonomatic Neuropathy NCT06461377 · ClinicalTrials.gov ↗ · Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)	Phase 4	Recruiting	2024-06	China
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction NCT05410925 · ClinicalTrials.gov ↗ · ST Elevation Myocardial Infarction	Phase 4	Recruiting	2023-04	China
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma NCT07294625 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase EARLY_PHASE1	Recruiting	2025-12	China
Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC NCT07646639 · ClinicalTrials.gov ↗ · Rectal Cancer, Radiotherapy Drugs: Aldesleukin, Capox, Sintilimab	Phase 2	Recruiting	2026-05	China
Effect of Individualized Exercise in Elderly Patients With Coronary Heart Disease NCT06588231 · ClinicalTrials.gov ↗ · Coronary Heart Disease	Not applicable	Recruiting	2023-10	China
A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer NCT07455019 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 2	Recruiting	2025-05	China
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement NCT04432714 · ClinicalTrials.gov ↗ · DLBCL, Untreated, MYC Gene Rearrangement Drugs: Cyclophosphamide, Doxorubicin, Etoposide	Phase 1/2	Recruiting	2020-06	China
Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes NCT07558863 · ClinicalTrials.gov ↗ · Type 2 Diabetes, Diabetes With Diabetic Autonomic Neuropathy (Diagnosis)	Phase 4	Recruiting	2026-04	China
PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. NCT07410520 · ClinicalTrials.gov ↗ · Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL) Drugs: Methotrexate, Orelabrutinib, Rituximab	Phase 2	Recruiting	2026-02	China
A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide. NCT05967949 · ClinicalTrials.gov ↗ · PTCL	Observational	Recruiting	2023-04	China
Whole Body MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Radiographic axSpA and Non-radiographic axSpA NCT07230327 · ClinicalTrials.gov ↗ · Spondyloarthritis (SpA), Whole-body MRI (WBMRI)	Observational	Recruiting	2022-01	China
Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes NCT07608978 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL) Drugs: Pola-R-Chp, Zanubrutinib	Phase 2	Recruiting	2026-06	China
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma NCT05613478 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Immunotherapy, Preoperative Drugs: Apatinib Mesylate, Camrelizumab	Phase 3	Recruiting	2023-01	China
Multi-parametric MRI and Dual-energy CT in Patients of Gastric Cancer NCT05508126 · ClinicalTrials.gov ↗ · Gastric Cancer Stage	Observational	Recruiting	2021-11	China
Prospective Study on Exemption of Tumor Bed Boost Radiotherapy for pCR Patients After Breast Conserving Surgery With Neoadjuvant Therapy NCT07113613 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	2025-01	China
Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN NCT05817955 · ClinicalTrials.gov ↗ · MDS/MPN	Phase 2	Recruiting	2022-11	China
Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib NCT07396454 · ClinicalTrials.gov ↗ · HER2-Negative Breast Cancer	Phase 2	Recruiting	2026-02	China
Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study NCT04964310 · ClinicalTrials.gov ↗ · Acetaminophen, Drug-Induced Liver Injury, Pharmacogenetics	Observational	Recruiting	2020-08	China
CPVI With Modified Linear Ablation Versus CPVI in Patients With Long-standing Persistent Atrial Fibrillation (SINUS) NCT06516822 · ClinicalTrials.gov ↗ · Long-standing Persistent Atrial Fibrillation, Ablation	Not applicable	Recruiting	2024-07	China
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer NCT07464756 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma Drugs: Apatinib, S-1 & Oxaliplatin, SHR-1701	Phase 2	Recruiting	2026-04	China
CSP Versus BiVP for Heart Failure Patients With RVP Upgraded to Cardiac Resynchronization Therapy NCT06241651 · ClinicalTrials.gov ↗ · Conduction System Pacing, Biventricular Pacing, Cardiac Resynchronization Therapy	Not applicable	Recruiting	2024-01	China
A Randomized Controlled Trial of LOT-CRT Versus conventionaL BiVP in Heart Failure Patients With NICD NCT06061627 · ClinicalTrials.gov ↗ · Heart Failure, Intraventricular Block	Not applicable	Recruiting	2023-09	China
Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer NCT05800054 · ClinicalTrials.gov ↗ · Esophageal Neoplasms, Adverse Drug Event Drugs: Cisplatin, Docetaxel	Not applicable	Recruiting	2021-01	China
To Evaluate the Effectiveness and Safety of Mastectomy Combined With Immediate Breast Reconstruction in Breast Cancer (NJMU-Reconstruction Cohort) NCT06817954 · ClinicalTrials.gov ↗ · Breast Cancer	Not applicable	Recruiting	2025-01	China
Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma NCT06563869 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Recruiting	2024-02	China
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer NCT06341894 · ClinicalTrials.gov ↗ · Early Breast Cancer Drug: Dalpiciclib	Phase 2	Recruiting	2023-11	China
Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT NCT07309211 · ClinicalTrials.gov ↗ · SCLC, Limited Stage	Observational	Recruiting	2025-07	China
Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy NCT07056010 · ClinicalTrials.gov ↗ · Gastric Cancer	Not applicable	Recruiting	2024-11	China
Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC NCT05956639 · ClinicalTrials.gov ↗ · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	Phase 3	Recruiting	2023-06	China
AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT NCT07250347 · ClinicalTrials.gov ↗ · Gastric Cancer Stage, Gastric Cancer Patients Undergoing Gastrectomy	Observational	Recruiting	2025-08	China
A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer NCT06001086 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	2023-11	China
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC NCT05983783 · ClinicalTrials.gov ↗ · Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemotherapy Effect Drugs: Docetaxel, Rezvilutamide	Phase 3	Recruiting	2023-08	China
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma NCT05494060 · ClinicalTrials.gov ↗ · Carcinoma, Gastrointestinal Diseases, Stomach Cancer Drugs: Anlotinib hydrochloride, Penpulimab, Xelox	Phase 2	Recruiting	2022-03	China
Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis NCT04592640 · ClinicalTrials.gov ↗ · Chronic Kidney Diseases, Calciphylaxis, Calcific Uremic Arteriolopathy	Phase EARLY_PHASE1	Recruiting	2018-09	China
Application of Sodium Bicarbonate Ringer's Solution in Laparoscopic Hepatectomy NCT05830136 · ClinicalTrials.gov ↗ · Hepatic Ischemia	Not applicable	Recruiting	2022-02	China
7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy NCT07232095 · ClinicalTrials.gov ↗ · Helicobacter Pylori	Phase 4	Recruiting	2026-01	China
Total Meso-rectal Excision Versus Transanal Local Excision Followed by Radiotherapy for T2N0M0 Distal Rectal Cancer NCT04098471 · ClinicalTrials.gov ↗ · Rectal Cancer	Not applicable	Recruiting	2021-10	China
Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma NCT06698692 · ClinicalTrials.gov ↗ · ESCC Drug: Trilaciclib	Observational	Recruiting	2024-04	China
Prospective Study on the Safety and Efficacy of Robot-Assisted Laparoscopic Partial Nephrectomy With Renal Artery Off-Clamp in the Treatment of cT1 Renal Tumors NCT06908902 · ClinicalTrials.gov ↗ · RCC, Renal Cell Cancer, Partial Nephrectomy	Not applicable	Recruiting	2024-12	China
Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery NCT06762782 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC), Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation	Phase 2	Recruiting	2025-02	China
The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies NCT07002112 · ClinicalTrials.gov ↗ · Relapsed/Refractory B-cell Malignancies	Phase 1	Recruiting	2025-05	China
An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies NCT07668453 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms Drugs: Adebrelimab, Albumin-Bound Paclitaxel /nab-Paclitaxel, Gemcitabine	Phase 2	Recruiting	2025-10	China
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma NCT06988956 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	2024-03	China
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer. NCT07394387 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer (TNBC) Drugs: Abraxane, Carboplatin, Sintilimab	Phase 2	Recruiting	2025-01	China
Comparison of Segmentectomy Versus Lobectomy for Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field NCT04944563 · ClinicalTrials.gov ↗ · Lung Neoplasms, Surgery	Not applicable	Recruiting	2021-07	China
Predicting Ventilator-associated Lower Respiratory Tract Infection Outcomes Using Sequenced-based Early Microbiological Response NCT06467864 · ClinicalTrials.gov ↗ · Pneumonia, Ventilator-Associated, Respiratory Tract Infections, Prognosis	Observational	Recruiting	2024-04	China
Comparing the Incidence of Parastomal Hernia After Mesenteric Molding Suturing and Non-molding Suturing in Colostomy Surgery NCT06674187 · ClinicalTrials.gov ↗ · Parastomal Hernia	Not applicable	Recruiting	2024-12	China

Showing the 100 most recently updated of 205 trials (recruiting first). The rest are in the country registers linked in each row.

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in The First Affiliated Hospital with Nanjing Medical University trials

90 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 50 more in the trial list above.

Conditions in The First Affiliated Hospital with Nanjing Medical University trials

271 conditions

Breast Cancer9 Gastric Cancer5 Hepatocellular Carcinoma4 Gastric Adenocarcinoma4 Esophageal Squamous Cell Carcinoma4 Immunotherapy3Gastric Cancer Stage III3Rectal Cancer3Relapsed/Refractory B-cell Malignancies3Metastatic Prostate Cancer3Rhinitis, Allergic3PTCL2DLBCL2 Acute Myocardial Infarction2 Multiple Myeloma (MM)2Gastric or Gastroesophageal Junction Adenocarcinoma2Non Muscle Invasive Bladder Cancer2 Pancreatic Cancer2 Advanced Breast Cancer2Coronary Artery Calcification2Acute Myeloid Leukemia2Preoperative2Breast Neoplasms2 Rheumatoid Arthritis2

By trial register

Register	Trials	Recruiting
Clinical trials in China	205	132

A trial with sites in more than one country appears in each of those registers; recruiting counts cover the trials listed on this page.

Other sponsors in Breast Cancer

Sponsor	Trials
Fudan University	48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	21
Second Affiliated Hospital, Zhejiang University, School of Medicine	19
AstraZeneca	15
Shengjing Hospital	15
Pfizer	12
Sichuan Baili Pharmaceutical	12
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	12
Hoffmann-La Roche	10
Ruijin Hospital	10

Sponsors with the most current trials registered for this condition.

Questions about The First Affiliated Hospital with Nanjing Medical University trials

How many clinical trials does The First Affiliated Hospital with Nanjing Medical University sponsor?

The First Affiliated Hospital with Nanjing Medical University is the lead sponsor of 205 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are The First Affiliated Hospital with Nanjing Medical University trials recruiting?

Yes. 132 of its 205 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is The First Affiliated Hospital with Nanjing Medical University testing?

Its current trials name 90 drugs and biologicals as interventions. The most frequent are Sintilimab (7), Adebrelimab (6), Orelabrutinib (5), Docetaxel (4) and Lenalidomide (4). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

The First Affiliated Hospital with Nanjing Medical University clinical trials